Fair Isaac Corporation (FICO) shares fell 27% on September 29, marking their worst day in over 30 years due to concerns about the growing use of the VantageScore model in home mortgage applications, which threatens FICO's market share. Despite this setback, FICO remains financially strong with $961 million in trailing twelve months free cash flow and aggressive share buybacks. The company’s updated guidance for fiscal year 2026 projects $2.53 billion in revenue and $42.43 adjusted earnings per share, with potential for earnings to exceed $50 per share in future years. Analysts see FICO’s stock as undervalued, estimating a fair value of $800 per share even with conservative earnings and valuation assumptions, suggesting a buying opportunity amid current price weakness.
Fair Isaac Corporation shares faced a major drop recently. For readers following financial stocks, here is Pluang's market snapshot as of Sep 30, 2026 04:22 WIB: Of 85 priced Financials-sector US stocks, 32 rose and 53 fell. Notable movers include LMND at USD 43.92 with a 1-day change of -2.25%, HBAN at USD 15.34 down 1.92%, and BTBT at USD 1.65 down 1.79% with 83% buy order activity and a typical hold time of 13 days.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...
Concentrix Corporation reported mixed Q3 2026 results with earnings per share of $2.92, beating analyst expectations of $2.71. However, its revenue of $2.45 billion slightly missed the forecast of $2.48 billion. The company achieved a record free cas...
Accenture is set to report Q3 2026 earnings on October 1, with analysts forecasting $18.03 billion in revenue, a 5.6% increase year-over-year, and earnings per share around $3.18. The growth is fueled by strong demand for AI services, with 100 new ad...
Iovance Biotherapeutics shares jumped 31.48% after raising its 2026 revenue forecast, driven by strong demand for its cancer immunotherapy Amtagvi. SoundThinking's stock rose 50.09% following an acquisition agreement with Transom Capital Group, offer...
Shares of uniQure dropped 37.33% following mixed clinical data for its Huntington's disease gene therapy. Fair Isaac fell 26.52% after U.S. regulators expanded the use of competitor VantageScore in mortgage credit scoring, threatening its market posi...
